SCI — Investor Presentation 2020

Apr 15, 2020

Notes:

公司概況Profile

員工數Employee：269
設立日期：中華民國七十六年九月十八日
Date of establishment: Sep. 18, 1987
資本額Capital：新台幣795佰萬元(NTD 795mn)
營業項目Business：
原料藥API（68.15%）
中間體Intermediate（28.00%）
特用化學品 Custom-made chemicals（3.85%）

Notes:

a production line dedicated

製藥產業的上、中、下游 SCI’s position
基本原料 RM
上游Upstream

中間體Intermediate:
生產原料藥之
中間步驟所產出之產品Products before API

旭富營業範圍
SCI’s businesses

中游
Midstream
原料藥API:
製劑中之有效成分Curative ingredient

下游
Downstream
製劑: 成品藥 Formulation

Notes:

emulsifier, excipient

公司概況 Outline

Notes:

營運概況-IS
Unit: K NTD

Notes:

lackluster October sales

產品組合-Products

Notes:

產品組合-Products

Notes:

VA Series:
Valproic Acid, Divalproex Sodium, Sodium Valproate

適應症 Application：
癲癇(seizure)、躁鬱症(bipolar disorder)、
偏頭痛(migraine headaches)

Notes:

Half of sales from DIVA

S-MMAA / Duloxetine HCl
適應症 Application:
重鬱症(major depressive disorder)、廣泛性焦慮症(generalized anxiety disorder) 、糖尿病週邊神經痛
(diabetic neuropathy) 、纖維肌痛（Fibromyalgia)、
慢性腰痛(日本地區) lower back pain (only in Japan)

Notes:

4 billion

Pyrogallolaldehyde ( PGA)
Benserazide
治療帕金森氏症之中間體
Intermediate for Parkinson’s Disease

Notes:

249 million

Hydroxychloroquine sulfate
適應症 Application:
類風濕性關節炎(rheumatoid arthritis) 、瘧疾 (malaria)、
慢性多形性日光疹、慢性圓板狀紅斑症 (discoid and systemic lupus erythematosus)

Notes:

Pent-2 / Pentobarbital Sodium
鎮定安眠用中間體及原料藥
Intermediate and API for calmative

Notes:

Menthadienol, Olivetol, Ethyl Olivetolate
為Dronabinol (THC 四氫大麻酚)及Cannabidiol
(CBD大麻二酚) 之關鍵中間體
The key intermediates for Dronabinol (THC) and
Cannabidiol (CBD)
THC 適應症 Applications：
化療引起的噁心、嘔吐
Nausea and vomiting due to chemotherapy
愛滋病引起之厭食症 anorexia due to AIDS
CBD 適應症 Applications：
Epidiolex：兒童罕見癲癇以及多發性硬化症
For seizures in patients aged 2 years and older, and Multiple Sclerosis.

Notes:

CBD (Cannabidiol)
CBD之應用廣泛：從癲癇、巴金森氏症、阿茲海默症，到關節炎、躁鬱 、焦慮、失眠、止痛、抗發炎等。
市場預估：
美國市場：2020年預估值為美金290億 ?
全球大麻與其衍生物之應用(醫藥、保健、美容等)：美金兩千億?

旭富 CBD (Cannabidiol)
製程放大成功，12月取得外銷專用許可證
2020年初完成確效，申請製藥許可證及美國藥證 (US DMF)
開始業務開發與小量試銷

CBD (Cannabidiol)
Wide range of medical benefits, from epilepsy, Parkinson’s and Alzheimer’s disease, bipolar disorder, anxiety, pain, inflammation, to arthritis, insomnia, etc.
Market estimations:
US market: US$ 29 billions in 2020?
Total Cannabis Opportunity (pharmaceutical, nutraceutical, beauty, etc.): ~ US$ 200 billions ??
CBD (Cannabidiol) by SCI
Scale-up successfully, to obtain export license in Dec. 2019.
To complete validation by early 2020, to apply domestic license with TFDA and to file US DMF.
BD started, qualification / trials on-going.

LMTM 新藥代工 (1)

適應症 Application：
阿茲海默症(Alzheimer`s Disease):臨床3期進行中。

疾病現況
全球約有4~5千萬病人，隨著醫療的進步及人口老化，病人數持續增加。
目前並無可以停止或逆轉病程的藥，市面上的藥均只能短期緩解症狀。

LMTM 新藥代工 (2)

Application：
Alzheimer`s Disease: under phase 3 clinical trial

Status:
There are approximately 40-50 millions patients worldwide, and is increasing.
While there is no cure for Alzheimer's disease, stopping or slowing down its progression, but just a temporarily improvement on certain symptoms.

No.	API	DMF (USA)	CEP (EDQM)	MF (Japan)	DMF (Canada)	CGMP certified (TFDA)
1	Valproic Acid	2003	2004	2008	2008	2003
2	Probucol	2004		2017	2015	2015
3	Divalproex Sodium	2005			2010	2005
4	Propafenone Hydrochloride	2010	2012	2012	2012	2010
5	Duloxetine Hydrochloride	2011	2014	2017	2016	2012
6	Allopurinol	2011	2003			2004
7	Clindamycin Palmitate HCl	2011
8	Articaine Hydrochloride	2014	2014			2013
9	Hydroxychloroquine Sulfate	2014			2014	2014
10	Brinzolamide	2015		2017		2015
11	Sodium Valproate		2006	2017		2004
12	Pentobarbital Sodium		2011			2009
13	Methylphenidate HCl		2014			2011
14	Bisoprolol Fumarate					2006
15	Thiopental acid					2012
16	Loxoprofen Sodium Hydrate			2011		2012
17	Atomoxetine HCl					2016

簡 報 完 畢

敬 請 指 教

Notes: